Over the weekend, President Donald Trump endorsed the potential of psychedelic treatments and vowed to expedite their research and development as remedies for severe mental

Novartis has axed two late-stage programs in cancer-related blood clots after observing “inferior efficacy” in a clinical trial. The move marks a setback for a

Merck partner reveals first human data for PD-1xVEGF bispecific: Sino Biopharm revealed that six of 11 lung cancer patients responded to a low dose of

The investor Venrock will make $900 million on a relatively small $20 million investment into Kelonia Therapeutics, which on Monday agreed to sell itself to

LONDON – Boehringer Ingelheim is growing its artificial intelligence arm to the UK by building a new hub in central London and investing £150 million